Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Caris Life Sciences (NASDAQ: CAI) will present at the 44th Annual J.P.

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Caris will present and participate in a Q&A session on Monday, January 12, 2026 at 1:30 PM PT.

Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com. The company is described as a patient-centric AI TechBio and precision medicine firm using whole exome and whole transcriptome sequencing plus AI to build a multimodal clinico-genomic database and computing platform.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge MA, Tokyo and Basel; media and investor contact emails are provided for inquiries.

Argus Jan 5 session

-2.11% close to close Open Argus

Details

News Market Reaction – CAI

In the Jan 5 session, CAI declined 2.11%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Caris Life Sciences’ participation in a major healthcare investor confe...

Analysis

This announcement highlights Caris Life Sciences’ participation in a major healthcare investor conference, which primarily increases visibility rather than changing fundamentals. In recent months, the company emphasized alliance growth, major collaborations, and expanding research output, alongside Q3 revenue of $216.8 million and net income of $24.3 million. Investors may watch for any conference commentary that updates on partnerships, revenue trajectory, cash of $757.0 million, or strategic use of the company’s multimodal clinico-genomic platform.

Key Figures

Q3 2025 revenue: $216.8 million Prior-year Q3 revenue: $101.6 million Q3 operating income: $32.6 million +5 more

Q3 2025 revenue

$216.8 million

Quarter ended September 30, 2025; from 10-Q filing

Prior-year Q3 revenue

$101.6 million

Quarter ended September 30, 2024; comparison in 10-Q

Q3 operating income

$32.6 million

Quarter ended September 30, 2025; improved from operating loss

Q3 net income

$24.3 million

Quarter ended September 30, 2025; versus prior-year net loss

Nine-month 2025 revenue

$519.1 million

Nine months ended September 30, 2025; from 10-Q

Nine-month net loss

$150.0 million

Nine months ended September 30, 2025; reflects non-operating items

Cash and equivalents

$757.0 million

Balance at Q3 2025 period end; from 10-Q

Common shares outstanding

282.1 million

As of September 30, 2025; from 10-Q

Historical Context

5 past events · Latest: Dec 19

5 events

1. Dec 19

   Alliance expansion

   24h Move

   +0.3%

   Added Providence Swedish Cancer Institute to expand the Precision Oncology Alliance.

2. Dec 16

   Strategic collaboration

   24h Move

   +3.4%

   Multi-year Genentech collaboration with up to $1.1 billion in potential milestones.

3. Dec 04

   Scientific presentations

   24h Move

   +3.0%

   Showcased 19 breast cancer studies featuring multi-omics and AI-driven signatures.

4. Dec 02

   Alliance expansion

   24h Move

   +0.2%

   UAMS Winthrop P. Rockefeller Cancer Institute joined the Precision Oncology Alliance.

5. Nov 21

   Education program

   24h Move

   +0.3%

   Announced the 2025/2026 Fellows Forum class with access to CODEai database.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

comprehensive molecular profiling, clinico-genomic, rule 10b5-1 trading plan, 10-q, +2 more

6 terms

comprehensive molecular profiling medical

"Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing)..."

Comprehensive molecular profiling is a detailed laboratory analysis of a patient’s tissue or blood to identify genes, mutations, proteins and other biological markers that drive a disease. Think of it as creating a high-resolution blueprint or fingerprint of a condition so doctors and drug developers can match treatments to the underlying cause. For investors, it signals opportunities for targeted therapies, diagnostic tests and more precise drug development, which can concentrate benefit and reduce wasted spending.

clinico-genomic medical

"multimodal clinico-genomic database and computing capability needed to analyze..."

Clinico-genomic describes the combination of clinical patient information (symptoms, treatment outcomes, medical history) with genomic data (DNA changes and tumor genetics) to gain a fuller picture of disease and treatment response. For investors, this integrated approach can reveal which drugs are likely to work, identify new drug targets, and de-risk development programs — like fitting medical and genetic puzzle pieces together to predict which therapies will succeed in the market.

rule 10b5-1 trading plan financial

"These option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

10-q regulatory

"Caris Life Sciences (CAI) filed its Q3 2025 10‑Q."

A 10-Q is a company’s required quarterly filing with U.S. regulators that provides updated financial statements, management discussion of results, and disclosures about risks, legal matters and operational changes. Think of it as a quarterly report card and progress update that lets investors track recent performance, spot trends or warning signs between annual reports, and make informed buy/sell decisions based on the latest verified financial and business information.

View in glossary

8-k regulatory

"Caris Life Sciences, Inc. Reports Material Event on Form 8‑K..."

An 8-K is a public report companies must file with the U.S. Securities and Exchange Commission to disclose major events or changes that shareholders should know about, such as leadership changes, mergers, financial surprises, or legal developments. It matters to investors because it acts like a breaking-news alert for a company’s health and prospects—providing timely facts that can affect stock value and investment decisions.

View in glossary

derivative proceeding regulatory

"must beneficially own at least 3% ... to institute or maintain a derivative proceeding"

A derivative proceeding is a lawsuit filed by a shareholder on behalf of the company to challenge alleged wrongdoing by officers, directors or others in control, when the company itself has not pursued the claim. Think of it as an owner taking legal action to fix harm done to shared property because the people running it won’t act; outcomes can expose liability, change management practices, and affect a company’s finances and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44^th Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California.

Caris will present and participate in a Q&A session on Monday, January 12 at 1:30 PM PT. Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com.

About Caris Life Sciences

Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition.  Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Investor Relations: 
IR@CarisLS.com 
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302651930.html

SOURCE Caris Life Sciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Caris Life Sciences (CAI) present at the 44th Annual J.P. Morgan Healthcare Conference?

Caris will present on Monday, January 12, 2026 at 1:30 PM PT.

How can investors watch Caris (CAI) presentation from the J.P. Morgan Healthcare Conference?

A live webcast and replay will be available on the Investor Relations section of CarisLifeSciences.com.

What are the dates and location of the 44th Annual J.P. Morgan Healthcare Conference where Caris (CAI) will appear?

The conference runs January 12–15, 2026 in San Francisco, California.

What does Caris (CAI) say it specializes in?

Caris describes itself as an AI TechBio precision medicine company using whole exome and whole transcriptome sequencing plus AI to build a multimodal clinico-genomic database.

Where is Caris Life Sciences (CAI) headquartered and where are its offices?

Caris is headquartered in Irving, Texas with offices in Phoenix, New York, Cambridge MA, Tokyo and Basel.

Who should investors or media contact about Caris (CAI) J.P. Morgan presentation?

Investor inquiries: IR@CarisLS.com; Media: CorpComm@CarisLS.com.